GENE Genetic Technologies ADRs

Genetic Technologies Limited, a molecular diagnostics company, provides predictive testing and assessment tools to help physicians manage the women's health in Australia and the United States. The company's lead product is the BREVAGenplus, a clinically validated risk assessment test for non-hereditary breast cancer. It markets BREVAGenplus to healthcare professionals in breast health care and imaging centers, as well as to obstetricians/gynecologists and breast cancer risk assessment specialists, such as breast surgeons. The company has a research and service agreement with The University of Melbourne for the development and enhancement of the BREVAGenplus breast cancer risk assessment test, as well as a strategic alliance with Blockchain Global Limited. Genetic Technologies Limited was founded in 1989 and is headquartered in Fitzroy, Australia. This is an ADR of a company whose stock trades outside of the U.S. as the symbol AT:GTG.

$1.28  -0.02 (-1.54%)
As of 09/26/2022 16:30:00 EST     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  ADRs
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Diagnostics & Research
Index country:  Australia
Country of incorporation:  Australia
IPO date:  01/02/2003
Outstanding shares:  15,389,942
Average volume:  46,857
Market cap:   $20,006,925
Current dividend yield:  0.00%
All SEC filings:   SEC Edgar Online
Annual filings:      20-F
Sedol:      
Valuation   (See tab for details)
PE ratio:   0.00
PB ratio:   1.09
PS ratio:   0.00
Return on equity:   -18.28%
Net income %:   -27,617.56%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy